Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
As we mark another Breast Cancer Awareness Month, it’s worth noting the recent strides that have been made when it comes to diagnosing and treating the disease.
Breast cancer is the most common form of cancer in women in the U.S. Affecting one in eight women, breast cancer will be accountable for about 40,610 deaths this year, making it the second deadliest cancer in women – the first being lung cancer. About 252,710 new diagnoses are expected in 2017 alone, according to the American Cancer Society. Read more
Dextera Surgical today has seen shares fall more than 10% after releasing its preliminary earnings for the 3rd quarter, expecting to see revenue of approximately $568,000.
Analysts on Wall Street were expecting to see sales of around $1.1 million for the company, significantly higher than the preliminary numbers released. Read more
BTG said today it will pay up to $80 million to acquire specialized cardiovascular catheter developer Roxwood Medical.
In the deal, U.K.-based BTG will pay $65 million upon closure of the deal and an additional $15 million upon the completion of certain future commercial milestones. BTG said it expects the deal to be accretive to adjusted EPS from the 2nd year of ownership forward. Read more
The US government is pressuring India to halt the extension of price caps on medical devices and to allow businesses to withdraw their products from the market if they don’t want to sell at those rates, according to a report from The Hindu.
The push came from a senior US Trade Representative, according to the report, after the country has taken steps to limit the prices on stents, orthopedic knee implant devices and is considering further caps for other medical devices. Read more
Johnson & Johnson said today that it plans to shut down its 410-worker Animas insulin pump subsidiary, offering to help some 90,000 Animas patients transfer to products made by rival Medtronic.
The Chesterbrook, Pa.-based company said it will stop making its Animas Vibe and OneTouch Ping pumps, but will continue to provide customer service, training and warranty support during the transition to Medtronic pumps. Sales of the Animas pumps in the U.S. and Canada have already halted, with decision on markets outside the U.S. subject to talks with local authorities, the company said. Read more